Expertise in
23
conditions

Dr. Marlyn Mayo

Gastroenterology
University Of Texas Southwestern Medical Center
5323 Harry Hines Blvd, 
Dallas, TX 
Expertise in
23
conditions
University Of Texas Southwestern Medical Center
5323 Harry Hines Blvd, 
Dallas, TX 

Overview

Marlyn Mayo is a Gastroenterologist in Dallas, Texas. Dr. Mayo is highly rated in 23 conditions, according to our data. Her top areas of expertise are Primary Biliary Cholangitis, Cholangitis, Cirrhosis, Autoimmune Hepatitis, and Liver Transplant.

Her clinical research consists of co-authoring 77 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Gastroenterology

Licenses

Internal Medicine in TX

Hospital Affiliations

Parkland Health & Hospital System
UT Of Texas Southwestern University Hospital - William P. Clements Jr.

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

University of Texas Southwestern Medical Center
5323 Harry Hines Blvd, Dallas, TX 75390
Other Locations
Dallas County Hospital District
5200 Harry Hines Blvd, Dallas, TX 75235

Additional Areas of Focus

Dr. Mayo has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2026
Intervention Type: Drug
Study Drug: Volixibat
Study Phase: Phase 2
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: July 18, 2025
Intervention Type: Drug
Study Drug: Linerixibat
Study Phase: Phase 3
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
Enrollment Status: Completed
Publish Date: January 29, 2025
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 2 Open Label, Proof of Concept Study of HTD1801 (BUDCA) in Adult Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy - PRONTO-PBC
A Phase 2 Open Label, Proof of Concept Study of HTD1801 (BUDCA) in Adult Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy - PRONTO-PBC
Enrollment Status: Completed
Publish Date: April 24, 2024
Intervention Type: Drug
Study Drug: HTD1801 (BUDCA)
Study Phase: Phase 2
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)
A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

77 Total Publications

Comment on Ejaz et al. Letter to the Editor.
Comment on Ejaz et al. Letter to the Editor.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: October 30, 2025
Similar Doctors
Expertise in
20
conditions
Dr. Amit Singal
Gastroenterology
Expertise in
20
conditions
Dr. Amit Singal
Gastroenterology

UT Southwestern-Bill And Rita Clements Advanced Medical Imaging Center

2201 Inwood Rd, 
Dallas, TX 
 (0.7 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amit Singal is a Gastroenterologist in Dallas, Texas. Dr. Singal is highly rated in 20 conditions, according to our data. His top areas of expertise are Liver Cancer, Cirrhosis, Hepatitis C, Liver Transplant, and Colonoscopy.

Expertise in
42
conditions
Dr. Paul R. Tarnasky
Gastroenterology
Expertise in
42
conditions
Dr. Paul R. Tarnasky
Gastroenterology

Texas Digestive Disease Consultants

221 W Colorado Blvd PAV II,, Ste 630, 
Dallas, TX 
 (4.2 miles away)
214-941-6891
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Paul Tarnasky is a Gastroenterologist in Dallas, Texas. Dr. Tarnasky is highly rated in 42 conditions, according to our data. His top areas of expertise are Hereditary Pancreatitis, Acute Pancreatitis, Pancreas Divisum, Endoscopy, and Gastric Bypass.

Expertise in
11
conditions
Dr. Stuart Spechler
Gastroenterology
Expertise in
11
conditions
Dr. Stuart Spechler
Gastroenterology

Select Specialty Hospital-Dallas Downtown

3500 Gaston Ave, 
Dallas, TX 
 (3.5 miles away)
214-865-2241
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stuart Spechler is a Gastroenterologist in Dallas, Texas. Dr. Spechler is highly rated in 11 conditions, according to our data. His top areas of expertise are Gastroesophageal Reflux Disease (GERD), Barrett Esophagus, Esophagitis, Endoscopy, and Colonoscopy.

Frequently Asked Questions about Dr. Marlyn Mayo

How do I make an appointment with Dr. Marlyn Mayo?

You can book an appointment with Dr. Marlyn Mayo by calling their office at 214-645-8600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Marlyn Mayo a top-rated expert for Primary Biliary Cholangitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Marlyn Mayo is classified as an Elite expert for Primary Biliary Cholangitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Marlyn Mayo specialize in?

While Dr. Marlyn Mayo is a Gastroenterology, they have specific expertise in Primary Biliary Cholangitis, Cholangitis, and Cirrhosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Marlyn Mayo participate in research or clinical trials?

Yes. Dr. Marlyn Mayo has published 77 articles and abstracts on conditions like Primary Biliary Cholangitis. You can view a list of Dr. Marlyn Mayo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Marlyn Mayo accept my insurance?

Dr. Marlyn Mayo accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 214-645-8600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mayo's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 11 Advanced Conditions
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile